Nootropic
Armodafinil
SaveThe R-enantiomer of modafinil, FDA-approved for narcolepsy, obstructive sleep apnea, and shift-work disorder. Longer plasma half-life than racemic modafinil.
Quick verdict
A well-characterized prescription wakefulness agent with robust clinical-trial support for its approved indications.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Multiple large RCTs support efficacy for excessive sleepiness in narcolepsy and shift-work disorder. Maintains higher late-day plasma levels than modafinil, which may benefit sustained wakefulness.
Benefits
- FDA-approved for wakefulness in specific conditions
- Longer duration of action than racemic modafinil
- Well-characterized safety profile from clinical trials
Dosage notes
150–250 mg once daily in the morning (approved dosing). Lower doses may suffice for off-label use.
Side effects
- Headache
- Nausea
- Insomnia
- Anxiety
- Dizziness
Who should be cautious
Prescription-only. Contraindicated with certain cardiac conditions. Reduces efficacy of hormonal contraceptives. Risk of Stevens-Johnson syndrome (rare).
What this page cannot tell you
Off-label cognitive-enhancement data in healthy individuals is limited. Most trials are in clinical populations with excessive sleepiness.
Leaderboard scores
- Energy82
- Focus80
- Mood40
Write a review
Sign in to write a review.